Editorial: Response assessment of radioligand therapies

Egesta Lopci; Vikas Prasad

doi:10.3389/fonc.2022.904337

Editorial: Response assessment of radioligand therapies

Egesta Lopci, Vikas Prasad

Division of Nuclear Medicine

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Article number	904337
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.904337
State	Published - Jul 27 2022

Keywords

PET/CT
neuroendocrine tumors
prostate cancer
radioligand therapy
response assessment

Access to Document

10.3389/fonc.2022.904337

Cite this

@article{5bb80235847c47ef920b441431d11878,

title = "Editorial: Response assessment of radioligand therapies",

keywords = "PET/CT, neuroendocrine tumors, prostate cancer, radioligand therapy, response assessment",

author = "Egesta Lopci and Vikas Prasad",

year = "2022",

month = jul,

day = "27",

doi = "10.3389/fonc.2022.904337",

language = "English",

volume = "12",

journal = "Frontiers in Oncology",

issn = "2234-943X",

}

TY - JOUR

T1 - Editorial

T2 - Response assessment of radioligand therapies

AU - Lopci, Egesta

AU - Prasad, Vikas

PY - 2022/7/27

Y1 - 2022/7/27

KW - PET/CT

KW - neuroendocrine tumors

KW - prostate cancer

KW - radioligand therapy

KW - response assessment

UR - http://www.scopus.com/inward/record.url?scp=85135854437&partnerID=8YFLogxK

U2 - 10.3389/fonc.2022.904337

DO - 10.3389/fonc.2022.904337

M3 - Editorial

C2 - 35965585

AN - SCOPUS:85135854437

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 904337

ER -

Editorial: Response assessment of radioligand therapies

Keywords

Access to Document

Other files and links

Cite this